Compare Canopy Growth Corp (CGC) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Canopy Growth Corp vs 22nd Century Group Inc — how do they compare? Canopy Growth Corp trades at $0.96 (market cap $398.46M), while 22nd Century Group Inc trades at $4.27 (market cap $1.45M). The key difference: Canopy Growth Corp is far larger — about 274.8× 22nd Century Group Inc's market cap. Which is the better fit depends on your goals.
| CGC | XXII | |
|---|---|---|
Market Cap | $398.46M | $1.45M |
Sector | Health | Technology |
52-Week High | $1.92 | $1.47K |
52-Week Low | $0.86 | $3.90 |
Enterprise Value | $337.90M | -$6.78M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Canopy Growth (CGC) trades at $0.96, down 1.15% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported a net loss of $598.12 million in 2025, with revenue declining to $269 million, though recent quarterly earnings showed one beat and two misses against expectations. Cash flow remains negative, but the balance sheet shows improving debt-to-asset ratios, down to 33.13% in 2025 from 53.61% in 2023.
The outlook is cautious; while cost-cutting and restructuring efforts are underway, profitability remains elusive, and the stock faces risks including potential delisting due to low share price. Analyst sentiment is divided, with 33% recommending buy, 41% hold, and 26% sell. Investors should weigh the potential for a turnaround against significant operational and regulatory challenges in the cannabis sector.
XXII trades at $4.10, down 3.07% today, with a bearish technical signal from moving averages. The company shows severe financial distress with a negative gross profit margin of -52.19% and net income margin of -65.76% for 2025. Recent news highlights expansion of VLN reduced-nicotine cigarettes in California and New York, aiming to capture market share. A 20:1 reverse stock split occurred on June 12, 2026, to adjust share structure.
The outlook remains high-risk due to persistent losses and cash burn, though analyst consensus is 75% buy-rated. Investment opportunity hinges on successful commercialization of VLN products and FDA regulatory renewals. Key risks include execution challenges, intense competition, and reliance on financing to sustain operations amid negative cash flow from operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Canopy Growth Corp
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
